These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20093350)

  • 1. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
    Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience.
    Chrysochou C; Buckley DL; Dark P; Cowie A; Kalra PA
    J Magn Reson Imaging; 2009 Apr; 29(4):887-94. PubMed ID: 19306428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
    Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
    AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
    Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
    JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadolinium-Induced Fibrosis.
    Todd DJ; Kay J
    Annu Rev Med; 2016; 67():273-91. PubMed ID: 26768242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?
    Neuwelt EA; Hamilton BE; Varallyay CG; Rooney WR; Edelman RD; Jacobs PM; Watnick SG
    Kidney Int; 2009 Mar; 75(5):465-74. PubMed ID: 18843256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Gadolinium in Individuals with Reduced Kidney Function.
    Kalantari K; Swaminathan S
    Clin J Am Soc Nephrol; 2021 Feb; 16(2):304-306. PubMed ID: 33431379
    [No Abstract]   [Full Text] [Related]  

  • 9. Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice.
    Meng H; Grosse-Wortmann L
    J Cardiovasc Magn Reson; 2012 Aug; 14(1):56. PubMed ID: 22871150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The need for prophylactic hemodialysis to protect against nephrogenic systemic fibrosis in patients with end-stage renal disease receiving gadolinium-based contrast agents.
    Lee Y; Kim J; Kwon S; Jeong JC; Joo KW; Oh KH
    Acta Radiol; 2023 Aug; 64(8):2492-2496. PubMed ID: 37128169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
    Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
    Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.
    Gauthier ID; Macleod CA; Sathiadoss P; McGrath TA; Nair V; Schieda N
    Abdom Radiol (NY); 2022 Mar; 47(3):1196-1201. PubMed ID: 34997298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.
    McWilliams RG; Frabizzio JV; De Backer AI; Grinberg A; Maes BD; Zobel BB; Gottschalk A
    J Magn Reson Imaging; 2020 Feb; 51(2):607-614. PubMed ID: 31287213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.
    Starekova J; Bruce RJ; Sadowski EA; Reeder SB
    Radiology; 2020 Dec; 297(3):556-562. PubMed ID: 32990511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media.
    Rees O; Agarwal SK
    Clin Radiol; 2010 Aug; 65(8):636-41. PubMed ID: 20599066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
    Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA
    Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.
    Alhadad A; Sterner G; Svensson Å; Alhadad H; Leander P
    Scand J Urol Nephrol; 2012 Feb; 46(1):48-53. PubMed ID: 22008005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of renal dysfunction by point-of-care creatinine testing in patients undergoing peripheral MR angiography.
    Kalisz KR; Davarpanah AH; Usman AA; Collins JD; Carroll TJ; Carr JC
    AJR Am J Roentgenol; 2011 Aug; 197(2):430-5. PubMed ID: 21785090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NSF evaluation of gadolinium biodistribution in renally impaired rats: Using novel metabolic Gd2O3 nanoparticles coated with β-cyclodextrin (Gd2O3@PCD) in MR molecular imaging.
    Ashouri H; Riyahi Alam N; Khoobi M; Haghgoo S; Rasouli Z; Gholami M
    Magn Reson Imaging; 2024 Apr; 107():120-129. PubMed ID: 38215955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.
    Alfano G; Fontana F; Ferrari A; Solazzo A; Perrone R; Giaroni F; Torricelli P; Cappelli G
    Magn Reson Imaging; 2020 Jul; 70():1-4. PubMed ID: 32112811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.